Gland Pharma

Gland Pharma

1,921.00
+42.90
(2.28%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
31,649.71 Cr
EPS
42.40
PE Ratio
39.97
Dividend Yield
0.96 %
Industry
Healthcare
52 Week High
2,131.00
52 Week Low
1,277.80
PB Ratio
3.36
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from13 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+46.15 %
+46.15 %
Hold
Hold+23.08 %
+23.08 %
Sell
Sell+30.77 %
+30.77 %

Company News

View All News
Caret
neutral
Gland Pharma Ltd. witnessed a block trade worth Rs. 45.99 crores on the NSE. The transaction involved approximately 240,922 shares at a price of Rs. 1,909.00 per share.
positive
There is a possibility that cancer medications might be excluded from GST. This development could impact Gland Pharma, a pharmaceutical company that operates in the cancer treatment segment.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,591.70
#1 3,81,902.15
33.06
#1 54,729.00
9.71
#1 10,980
-19.84
40.16
6,002.50
1,59,347.52
69.37
9,712.00
18.67
2,191
26.74
39.26
1,551.60
1,25,323.95
23.09
28,409.50
7.12
5,291
9.88
46.33
3,643.30
1,23,305.83
60.50
11,539.40
6.99
1,911
19.91
53.31
1,291.30
1,07,768.16
#1 18.37
33,741.20
16.73
5,725
1.26
47.70
2,589.30
1,06,867.85
56.30
12,744.20
#1 20.90
2,007
-18.14
56.66
1,035.60
1,04,205.59
21.78
23,511.00
18.55
4,615
2.60
59.03
1,957.30
89,389.00
24.04
22,909.50
13.74
3,306
#1 51.64
52.36
30,630.00
65,086.61
45.33
6,684.70
9.64
1,414
11.55
36.70
5,336.00
63,799.88
27.97
13,458.30
3.70
2,216
21.39
59.78
Forecast
Actual
Growth Rate
Revenue Growth
-0.08 %
Net Income Growth
-9.58 %
Cash Flow Change
-8.23 %
ROE
-13.79 %
ROCE
-8.55 %
EBITDA Margin (Avg.)
-1.28 %

Quarterly Financial Results

Quarterly Financials
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
681
916
852
895
935
1,216
1,132
1,109
1,168
931
1,110
1,000
824
1,246
1,427
1,583
1,580
1,453
1,466
1,443
1,469
1,563
Expenses
395
472
534
595
560
718
704
714
755
587
748
649
673
915
1,049
1,189
1,179
1,137
1,109
1,024
1,077
1,138
EBITDA
286
445
318
299
375
498
428
395
414
344
363
351
151
332
377
394
401
316
357
418
392
425
Operating Profit %
38 %
47 %
36 %
31 %
37 %
38 %
35 %
33 %
32 %
32 %
28 %
31 %
14 %
24 %
24 %
23 %
23 %
19 %
21 %
26 %
24 %
24 %
Depreciation
24
24
25
25
25
25
26
28
31
35
37
38
38
65
81
105
93
92
94
96
96
101
Interest
1
1
1
1
1
1
1
1
2
1
2
3
2
5
6
5
10
6
6
23
7
12
Profit Before Tax
262
420
293
273
349
472
401
366
381
309
324
311
111
261
290
283
298
218
257
299
288
313
Tax
67
106
74
69
89
121
99
93
95
79
83
79
33
67
96
91
106
75
93
95
102
97
Net Profit
195
314
219
204
260
351
302
273
286
229
241
232
79
194
194
192
192
144
164
205
187
216
EPS in ₹
12.57
20.24
14.12
12.83
15.93
21.41
18.37
16.62
17.40
13.93
14.65
14.08
4.78
11.79
11.78
11.65
11.68
8.73
9.93
12.42
11.32
13.08

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
4,086
6,496
7,834
8,778
10,661
11,225
Fixed Assets
968
954
1,502
1,571
3,947
4,147
Current Assets
2,846
5,124
5,852
6,901
5,645
6,783
Capital Work in Progress
189
338
191
177
238
151
Investments
0
0
155
0
0
0
Other Assets
2,930
5,204
5,986
7,030
6,477
6,927
Total Liabilities
4,086
6,496
7,834
8,778
10,661
11,225
Current Liabilities
359
513
582
729
1,398
1,565
Non Current Liabilities
81
80
94
90
539
509
Total Equity
3,646
5,903
7,158
7,959
8,724
9,151
Reserve & Surplus
3,631
5,887
7,141
7,942
8,707
9,134
Share Capital
16
16
16
17
17
17

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
-67
323
-174
1,590
-1,552
2,199
Investing Activities
-761
-1,520
-999
1,211
-1,749
1,718
Operating Activities
701
605
791
364
997
915
Financing Activities
-7
1,239
35
15
-799
-434

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
58.25 %
58.14 %
58.02 %
58.00 %
58.00 %
57.87 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
4.91 %
0.00 %
3.59 %
6.88 %
4.47 %
5.04 %
6.90 %
7.39 %
DIIs
10.69 %
11.57 %
11.39 %
11.21 %
11.94 %
16.71 %
20.58 %
23.13 %
23.23 %
23.38 %
22.45 %
23.14 %
25.23 %
32.83 %
35.37 %
34.80 %
33.27 %
32.85 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
3.30 %
3.72 %
3.77 %
3.58 %
3.69 %
3.70 %
3.77 %
4.02 %
4.26 %
5.60 %
4.52 %
3.79 %
3.28 %
3.33 %
3.28 %
3.30 %
2.99 %
2.91 %
Others
27.76 %
26.58 %
26.81 %
27.21 %
26.37 %
21.71 %
17.78 %
14.98 %
14.64 %
13.16 %
10.27 %
15.22 %
10.04 %
5.12 %
5.04 %
5.04 %
5.01 %
5.02 %
No of Share Holders
84,467
98,203
1,09,326
1,09,097
1,09,098
1,17,339
1,27,879
1,48,469
1,50,578
1,81,747
1,61,627
1,36,021
1,22,375
1,22,665
1,22,358
1,21,075
1,13,788
1,10,671

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20 18
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.26 0.96

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
16 Aug 2024 DIVIDEND Dividend
₹ 20.00 /share
16 Aug 2024 1,800.25 1,958.25
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Aug 2024 1,800.25 1,849.00
04 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Nov 2024 1,675.30 1,644.85
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Feb 2025 1,672.75 1,530.45
20 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 May 2025 1,418.75 1,484.15
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Aug 2025 2,000.80 1,982.80
14 Aug 2025 DIVIDEND Dividend
₹ 18.00 /share
14 Aug 2025 1,484.15 1,950.30
28 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Aug 2025 1,484.15 1,928.25

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
Announcement under Regulation 30 (LODR)-Change in ManagementAug 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 28, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 28, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Rumour verification - Regulation 30(11)Aug 01, 2025
Clarification sought from Gland Pharma LtdAug 01, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Notice Of 47Th AGM Of Gland Pharma LimitedJul 31, 2025
Reg. 34 (1) Annual Report.Jul 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Board Meeting Intimation for Declaration Of Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 21, 2025
Gland Pharma Receives GMP Compliance Certificate From The Danish Medicines Agency For Aseptically Prepared Powder For Injection Infusion And InhalationJul 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 2025Jul 03, 2025
Closure of Trading WindowJun 27, 2025
Receipt Of EIR From US FDA For Companys JNPC Facility VisakhapatnamJun 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Update On ANSM Inspection At Cenexis Fontenay Manufacturing FacilityJun 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
Grant Of Stock Options (Grant I) Under Gland Pharma Employee Stock Option Scheme 2025 (ESOP 2025 Or Scheme)May 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
The 47Th AGM Of The Company Is Scheduled To Be Held On Thursday August 28 2025May 20, 2025
Board Fixes August 14 2025 As The Record Date For Final DividendMay 20, 2025

Technical Indicators

RSI(14)
Neutral
40.51
ATR(14)
Volatile
51.76
STOCH(9,6)
Neutral
24.32
STOCH RSI(14)
Neutral
29.99
MACD(12,26)
Bearish
-7.66
ADX(14)
Weak Trend
19.27
UO(9)
Bearish
40.15
ROC(12)
Downtrend And Accelerating
-3.37
WillR(14)
Neutral
-77.26

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Mid Cap Fund Direct-Growth
0.00%
-5651922
-1.39%
-1.21%
Mirae Asset Large & Midcap Fund Direct-Growth
0.00%
-2923448
-1.49%
-1.30%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-2900000
-1.80%
-1.61%
Nippon India Growth Mid Cap Fund Direct- Growth
0.00%
-2800000
-1.50%
-1.31%
ICICI Prudential India Opportunities Fund Direct - Growth
0.00%
-2217343
-1.54%
-1.67%
Mirae Asset Large Cap Fund Direct- Growth
0.00%
-2145611
-1.11%
-0.97%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
0.00%
-1952663
-1.55%
-1.28%
Nippon India Small Cap Fund Direct- Growth
0.00%
-1780371
-0.56%
-0.49%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-1466415
-0.66%
-0.59%
HDFC Large and Mid Cap Fund Direct- Growth
0.00%
-1400000
-1.09%
-1.08%
Mirae Asset Midcap Fund Direct - Growth
0.00%
-1378264
-1.67%
-1.60%
HDFC Manufacturing Fund Direct - Growth
0.00%
-1348515
-2.36%
-2.50%
Nippon India Pharma Fund Direct-Growth
0.00%
-1320549
-3.12%
-3.27%
Mirae Asset Focused Fund Direct - Growth
0.00%
-1146776
-2.95%
-2.60%
Nippon India ELSS Tax Saver Fund Direct-Growth
0.00%
-1100000
-1.48%
-1.29%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.00%
-955332
-0.44%
-0.39%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-947263
-3.20%
-3.57%
DSP Healthcare Fund Direct - Growth
0.00%
-920673
-5.96%
-5.52%
SBI Contra Direct Plan-Growth
0.00%
-813026
-0.36%
-0.31%
UTI Flexi Cap Fund Direct-Growth
0.00%
-788274
-0.63%
-0.55%
Canara Robeco Small Cap Fund Direct - Growth
0.00%
-732723
-1.17%
0.00%
Aditya Birla Sun Life Large Cap Direct Fund-Growth
0.00%
-716302
-0.49%
-0.42%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-700000
-3.59%
-2.57%
Nippon India Large Cap Fund Direct-Growth
0.00%
-675994
-0.32%
-0.37%
Quant Small Cap Fund Direct Plan-Growth
0.00%
-621279
-0.44%
0.00%

About Gland Pharma

Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years, 21 days)
Chairperson NameYiu Kwan Stanley Lau